Drug-induced (vancomycin, contrast, cisplatin, immune checkpoint inhibitors) early diagnosis biomarkers of kidney injury research: a prospective, observational cohort study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400086693

Enrollment

Unknown

Registered

2024-07-09

Start date

2024-08-01

Completion date

Unknown

Last updated

2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney injury

Interventions

NO-KI group (control group without AKI) and DI-KI group (experimental group with AKI) according to whether AKI occurred after the use of nephrotoxic drugs.:None

Eligibility

Sex/Gender

All

Age

18 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1 Agree to sign the informed consent form 2 Adult patients older than 18 years 3 were expected to receive a course of the corresponding nephrotoxic agent

Exclusion criteria

Exclusion criteria: 1 CKD stage 5 or receiving regular dialysis 2 Baseline serum creatinine = 4mg/dL(353.6µmol/L) on medication 3 Acute kidney injury occurred on admission 4 Renal transplant status or solitary kidney The course of nephrotoxic drugs is too short 6 Unable to tolerate multiple blood collections 7 The patient asked to withdraw

Design outcomes

Primary

Measure	Time frame
serum creatinine;BUN;Cys-C;RBP4;IL-2;NGAL;CLU;OPN;KIM- 1;	—

Countries

China

Contacts

Public ContactPan Kunming

Zhongshan Hospital Fudan University

panxso@163.com+86 21 6404 1990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026